Darelle Online Solutions Inc. (TSXV:DAR)

Ligand Pharmaceuticals Income Statement

Financials in millions CAD. Fiscal year is September - August.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	May 31, 2025	Aug 31, 2024	Aug 31, 2023	Aug 31, 2022	Aug 31, 2021	Aug 31, 2020
Revenue	0.05	0.07	0.05	0.15	0.26	0.15
Revenue Growth (YoY)	-21.97%	27.60%	-62.80%	-43.79%	77.66%	11.30%
Cost of Revenue	-	-	0.01	0.1	0.13	0.06
Gross Profit	0.05	0.07	0.05	0.04	0.13	0.08
Selling, General & Admin	0.24	0.23	0.19	0.21	0.28	0.32
Operating Expenses	0.24	0.23	0.19	0.21	0.28	0.37
Operating Income	-0.19	-0.16	-0.14	-0.17	-0.15	-0.29
Interest Expense	-0	-0	-	-0	-0	-
Other Non Operating Income (Expenses)	-0.02	-0.02	-0	-0.01	0.02	0
EBT Excluding Unusual Items	-0.21	-0.18	-0.15	-0.19	-0.14	-0.29
Asset Writedown	-	-	-	-	-	-0.14
Other Unusual Items	0.02	0.02	-	0	0.01	0.04
Pretax Income	-0.19	-0.16	-0.15	-0.18	-0.13	-0.4
Net Income	-0.19	-0.16	-0.15	-0.18	-0.13	-0.4
Net Income to Common	-0.19	-0.16	-0.15	-0.18	-0.13	-0.4
Shares Outstanding (Basic)	2	2	2	2	2	2
Shares Outstanding (Diluted)	2	2	2	2	2	2
EPS (Basic)	-0.08	-0.07	-0.06	-0.07	-0.05	-0.16
EPS (Diluted)	-0.08	-0.07	-0.06	-0.07	-0.05	-0.16
Gross Margin	100.00%	100.00%	85.19%	30.55%	48.71%	55.76%
Operating Margin	-374.80%	-232.91%	-268.08%	-115.08%	-58.29%	-198.90%
Profit Margin	-383.70%	-232.58%	-273.12%	-126.49%	-49.51%	-272.17%
EBITDA	-	-	-	-	-	-0.24
EBITDA Margin	-	-	-	-	-	-163.92%
D&A For EBITDA	-	-	-	-	-	0.05
EBIT	-0.19	-0.16	-0.14	-0.17	-0.15	-0.29
EBIT Margin	-	-232.91%	-268.08%	-115.08%	-58.29%	-198.90%

Updated Jan 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.